Relationship of plasma anti-heparin activity and platelet survival time in coronary disease.
D001241:Aspirin / Q000627:therapeutic use; D001779:Blood Coagulation Factors; D001792:Blood Platelets / Q000503:physiopathology*; D002470:Cell Survival / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood*; D004176:Dipyridamole / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D010978:Platelet Factor 4; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013997:Time Factors
D001779:Blood Coagulation Factors; D010978:Platelet Factor 4; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone; D007213:Indomethacin